Hereditary Cancer Retesting After a Negative Result: What Labs Should Know in 2026
Short answer: Retesting after a negative hereditary cancer result is clinically reasonable when the original test was narrow, such as BRCA1/2 only, and family history remains strong. Published retesting cohorts found new pathogenic variants in roughly 5 to 17 percent of patients, but coverage is not guaranteed, so labs should document medical necessity before ordering.
Why is hereditary cancer retesting in the news now?
A Washington Post report on October 11, 2026, relayed by HealthDay on October 13, put a long-quiet issue back in front of clinicians: many women tested for inherited cancer risk years ago may have received only part of the picture. Breast cancer risk testing began in 1996 and examined just two genes, BRCA1 and BRCA2. After the U.S. Supreme Court struck down the patents on those genes and tests in 2013, other laboratories began offering panel tests covering several dozen genes.
Dr. Sofia Merajver of the University of Michigan Rogel Cancer Center estimated that thousands of people may need a new test. Dr. Siddhartha Yadav of Mayo Clinic voiced concern that too few doctors raise the topic, noting that patients who arrive with cancer are often past the point of prevention discussions. Those are clinician perspectives, not new guideline mandates, but they signal that ordering providers and patients are likely to start asking labs about retesting.
What does the evidence say about retest yield?
Two published cohorts give labs a realistic range. In a study by Jordan Lerner-Ellis and George Charames, 110 women who had previously tested negative for BRCA1 and BRCA2 pathogenic variants were retested with a 20-gene breast and ovarian cancer panel at Mount Sinai Hospital's Advanced Molecular Diagnostics Laboratory in Toronto between March 2017 and March 2019. Six of 110 women, or 5.5 percent, carried pathogenic variants in other genes. Among women who had cancer, the yield was 6.5 percent (6 of 93), including 22.2 percent (2 of 9) of women with ovarian cancer. None of the 17 unaffected women had a pathogenic finding. The genes involved were RAD51C (two cases), BRIP1, PALB2, PMS2, and PTEN.
A second study, by Dettwyler and colleagues in Familial Cancer in 2022, reviewed charts at a cancer genetics clinic from January 1998 to March 2019. Of 6,556 patients identified, 139 had germline testing on two or more dates at least a year apart with no pathogenic or likely pathogenic variant on the first-line test. On retesting, 24 of the 139 patients, about 17 percent, had a pathogenic or likely pathogenic variant. Management recommendations changed significantly for 66 percent of the patients with a positive finding.
What about variants of uncertain significance?
Broader panels also raise the odds of an inconclusive result. In the Toronto cohort, 44 of 110 women, or 40 percent, had a variant of uncertain significance. The Dettwyler study found 14 patients with such a variant. The National Cancer Institute notes that most variants of uncertain significance later prove harmless, and advises people who receive one to stay in touch with the ordering provider.
The reclassification data explain why. A retrospective study of 1.45 million individuals tested at Myriad Genetics between 2006 and 2016, published in JAMA in 2018, found that 25 percent of reported variants of uncertain significance were later reclassified, resulting in 59,955 amended reports. Of the reclassified variants, 91 percent were downgraded to benign or likely benign and 9 percent were upgraded to pathogenic or likely pathogenic. For a lab, that means a report is a snapshot, and a recontact process matters.
What does NCI guidance say about when to retest?
NCI guidance summarized in the October coverage says repeating the same test usually is not needed, because DNA does not change. Broader testing may make sense if an earlier test was negative despite a strong family history of cancer, or if a person develops a cancer that the first test did not cover. That framing matters for operations: the clinical question is usually not a repeat of the same assay but a different, wider one, and requisitions should say so clearly.
For the criteria that most payers and laboratories use to judge hereditary testing appropriateness, see our explainer on NCCN hereditary cancer testing guidelines. For Medicare-specific policy language, see the MolDX inherited cancer syndromes LCD and billing article.
What are the coverage and billing risks for labs?
The October coverage states plainly that insurance does not always pay for retesting, and cost can be a hurdle. It does not describe specific payer criteria, so labs should not assume any one policy. The practical risks fall into three groups.
First, medical necessity documentation. A patient with a prior negative result and no change in history may look like a repeat order to a claims edit. The record should show what was tested originally, which genes were not covered, and what family history or new diagnosis justifies broader testing. Second, duplicate-service edits: a payer system may compare the new claim against the earlier one, and our guide to Medicare duplicate lab test denials and modifier 91 explains how repeat-test logic can trigger denials. Third, prior authorization and patient communication: because coverage is uncertain, patients may face out-of-pocket exposure, so financial counseling before collection is prudent.
Denial prevention is also a volume question. Our review of the 2025 lab claim denial rate report shows why front-end checks matter before a claim is ever filed.
What should labs and medical directors do now?
Labs can build a retesting-ready workflow without waiting for new policy. Requisition forms can capture prior testing history, including laboratory, date, and genes covered. Report templates can state the genes and variant classes assessed, so a future clinician can tell what a negative result did and did not exclude. A variant reclassification and recontact policy can specify who is notified, through which ordering provider, and how it is documented.
Medical directors and genetic counselors can also help ordering clinicians separate three situations: patients who had narrow testing and strong family history, patients who developed a new cancer outside the original panel, and patients whose original test already covered the relevant genes and for whom retesting is unlikely to add value. The yield data above suggest the first two groups are where new findings occur, and the Toronto data show no pathogenic findings among 17 unaffected women, a small sample that should not be over-read.
Revenue cycle teams should track retest orders as their own category for a quarter, noting payer, denial reason, and appeal outcome. That gives the lab its own coverage evidence instead of relying on assumptions. For workflow support across ordering, documentation, and claims, visit ScreenMyGene.
Frequently asked questions
Is repeating the same hereditary cancer test usually necessary?
Usually not. NCI guidance says DNA does not change, so repeating the identical test generally adds little. Broader testing may make sense when an earlier test was negative despite strong family history or when a new cancer arises that the first test did not cover.
How often does retesting find a new pathogenic variant?
It depends on the cohort. A Toronto study retesting 110 BRCA1/2-negative women with a 20-gene panel found pathogenic variants in 5.5 percent. A genetics clinic review found about 17 percent among 139 patients retested at least a year after an uninformative result.
Will insurance cover hereditary cancer retesting?
Not always. Coverage reporting in October 2026 states that insurance does not always pay for retesting and did not describe specific payer criteria. Labs should confirm the applicable policy, document why broader testing is needed, and counsel patients about possible cost before collection.
Do variants of uncertain significance change over time?
Yes. A JAMA study of 1.45 million individuals tested between 2006 and 2016 found 25 percent of variants of uncertain significance were later reclassified. Of those, 91 percent were downgraded to benign or likely benign and 9 percent were upgraded to pathogenic or likely pathogenic.
What should a lab document for a retest order?
Document the prior test, date, laboratory, and genes covered; the family history or new diagnosis prompting broader testing; and the clinical decision the result could change. Clear records support medical necessity review and help distinguish a legitimate broader test from a duplicate service.
This article is for educational purposes only and does not constitute legal, regulatory, billing, or clinical advice. Coverage varies by payer and plan; confirm requirements with the applicable policy and your compliance counsel.
Sources: The Washington Post, "Women once cleared by genetic tests for cancer risks now consider retesting" (October 11-12, 2026), as reported by HealthDay (October 13, 2026); Lerner-Ellis and Charames, retesting of BRCA1/2-negative women using a 20-gene panel, J Med Genet (2019); Dettwyler et al., "Outcomes of retesting in patients with previously uninformative cancer genetics evaluations," Fam Cancer 21(3):375-385 (2022); Myriad Genetics press release on JAMA variant reclassification study (September 25, 2018); U.S. National Cancer Institute guidance as summarized in the HealthDay report.